98%
921
2 minutes
20
Faricimab, a new drug for diabetic macular edema (DME), was made available in Japan in 2022. However, few reports have been published about its treatment outcomes in clinical practice. To assess the short-term outcomes of intravitreal faricimab (IVF) in patients with DME, the records of patients with DME receiving IVF therapy between July 2022 and July 2023 at Juntendo University Hospital were retrospectively reviewed. Their best-corrected visual acuities in the logarithm of the minimum angle of resolution units and central macular thicknesses were compared at baseline and one month after the final IVF. Eighteen patients and 22 eyes were included and allocated to the naïve and switched groups: 12 cases (15 eyes) and 6 cases (7 eyes), respectively. The best-corrected visual acuity improved for the naïve group, but no difference was observed for the switched group. In contrast, the central macular thickness improved for both the naïve and switched groups. IVF demonstrated good short-term outcomes for DME, suggesting that it is effective for DME in clinical practice.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074261 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0323088 | PLOS |
Diabetes Res Clin Pract
September 2025
Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address:
Aims: To evaluate the association between intravitreal anti-VEGF therapy and lower extremity complications in diabetic eye disease (DED), and compare risks among ranibizumab, aflibercept, and bevacizumab.
Methods: This retrospective cohort study used a U.S.
Surv Ophthalmol
September 2025
Yong Loo Lin School of Medicine, National University of Singapore, Singapore; National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Programme for Ocular Inflammation & Infection Translational Resear
The Choroidal Vascularity Index (CVI), derived from optical coherence tomography (OCT), has emerged as a potential biomarker for detecting vascular changes. Understanding its variability across physiological states, ocular conditions, and systemic diseases is crucial for its integration into clinical practice. We evaluated variations in CVI across different physiological states (e.
View Article and Find Full Text PDFHum Cell
September 2025
Eye Hospital, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Age-related eye diseases (AREDs) are the leading cause of visual impairment in the elderly, affecting the structure of the anterior and posterior segments of the eye, significantly reducing the quality of life of patients, and even leading to irreversible blindness. Typical AREDs include age-related cataract (ARC), dry eye disease (DED), age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy (DR), the global prevalence of which continues to rise, becoming a serious public health concern. SIRT1 is an NAD + dependent deacetylase, which plays an important physiological regulatory role in ocular tissues, mainly affecting gene expression and various cellular processes by regulating the acetylation status of substrate proteins.
View Article and Find Full Text PDFSurv Ophthalmol
September 2025
Department of Ophthalmology, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Weifang 261041, China.
Lipid metabolism plays a critical role in maintaining normal physiological functions and is strongly linked to the pathogenesis of ocular vascular diseases. This review examines how disorders of lipid metabolism drive progression in ocular vascular diseases, including diabetic retinopathy, age-related macular degeneration, retinal vascular occlusive diseases, and retinopathy of prematurity. These disorders are classified as a related group due to their common feature of impaired ocular vascularization.
View Article and Find Full Text PDFClin Ophthalmol
August 2025
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, People's Republic of China.
Purpose: To evaluate the caregiver burden and its associated factors among patients receiving anti-VEGF intravitreal injections for age-related macular degeneration (AMD) and diabetic retinopathy (DR) in a tertiary hospital in Guangzhou, China.
Methods: This cross-sectional study recruited 88 patients who received intravitreal anti-VEGF injections and their primary caregivers. Patients completed the Activities of Daily Living (ADL) scale, while caregivers completed the Zarit Burden Interview (ZBI) and the Connor-Davidson Resilience Scale (CD-RISC).